Daftar Pustaka

1. Denny GB, Deger SM, Chen G, Bian A, Sha F, Booker C, et al. Leucine disposal rate for
assessment of amino acid metabolism in maintenance hemodialysis patients. BMC Nutr.
2016;1–13.
2. Stegmayr B. Dialysis Procedures Alter Metabolic Conditions. Nutrients. 2017;9(6):548.
3. Bermúdez-López, Marcelino, et al. "New perspectives on CKD-induced dyslipidemia."
Expert opinion on therapeutic targets 21.10 (2017): 967-976.
4. Phukan, Rashmi Rekha, and Rohini K. Goswami. "Unusual dyslipidemia in patients with
chronic kidney diseases." Journal of clinical and diagnostic research: JCDR 11.1 (2017):
BC01.
5. Wanner, Christoph, and Marcello Tonelli. "KDIGO Clinical Practice Guideline for Lipid
Management in CKD: summary of recommendation statements and clinical approach to the
patient." Kidney international 85.6 (2014): 1303-1309.
6. Wanner, Christoph, et al. "Randomized controlled trial on the efficacy and safety of
atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and
baseline characteristics." Kidney and Blood Pressure Research 27.4 (2004): 259-266.
7. Fellström B, Holdaas H, Jardine AG, et al. Effect of rosuvastatin on outcomes in chronic
haemodialysis patients: baseline data from the AURORA study. Kidney Blood Press Res.
2007;30(5):314–322.
8. Group, SHARP Collaborative. "Study of Heart and Renal Protection (SHARP): randomized
trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438
patients with chronic kidney disease." American heart journal 160.5 (2010): 785-794.
9. Zhang, Yan, et al. "Non-HDL-C is a better predictor for the severity of coronary
atherosclerosis compared with LDL-C." Heart, Lung and Circulation 25.10 (2016): 975-
981.
10. Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, et al. Atherogenic Index of Plasma
(AIP): A marker of cardiovascular disease. Med J Islam Repub Iran. 2015;29:240. Published
2015 Jul 25.
11. Moradi H, Vaziri ND, Section N, Affairs V, Beach L, St E, et al. Molecular mechanisms of
disorders of lipid metabolism in chronic kidney disease. 2018;(1):146–61.
12. Kronenberg F. High-Density Lipoprotein in Chronic Kidney Diseases—The Devil Is in the
Detail. J Am Soc Nephrol [Internet]. 2018;ASN.2017070798.
13. Chan, Doris T., et al. "Chronic kidney disease delays VLDL-apoB-100 particle catabolism:
potential role of apolipoprotein C-III." Journal of lipid research 50.12 (2009): 2524-2531.
14. Kuznik, A., J. Mardekian, and L. Tarasenko. 2013. Evaluation of cardiovascular disease
burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis
of national health and nutritional examination survey data, 2001-2010. BMC nephrology 14:
132
15. Longenecker, J. C., J. Coresh, N. R. Powe, A. S. Levey, N. E. Fink, A. Martin, and M. J.
Klag. 2002. Traditional cardiovascular disease risk factors in dialysis patients compared
with the general population: the CHOICE Study. J Am Soc Nephrol 13: 1918-1927
16. Dallinga-Thie, G. M., Kroon, J., Borén, J., & Chapman, M. J. (2016). Triglyceride-rich
lipoproteins and remnants: targets for therapy?. Current cardiology reports, 18(7), 67.
17. Helkin, A., Stein, J. J., Lin, S., Siddiqui, S., Maier, K. G., & Gahtan, V. (2016).
Dyslipidemia part 1—review of lipid metabolism and vascular cell physiology. Vascular and
 endovascular surgery, 50(2), 107-118.
18. N.D. Vaziri, and K. Liang: Down-regulation of VLDL receptor expression in chronic
experimental renal failure. Kidney Int. 51, 913–9 (1997) DOI: 10.1038/ki.1997.129
19. N.D. Vaziri, and K. Liang: Down-regulation of tissue lipoprotein lipase expression in
experimental chronic renal failure. Kidney Int. 50, 1928–35 (1996) DOI:
10.1038/ki.1996.515
20. Moradi, H., & Vaziri, N. D. (2018). Molecular mechanisms of disorders of lipid metabolism
in chronic kidney disease.
21. B. Stegmayr, T. Olivecrona, and G. Olivecrona: Lipoprotein lipase disturbances induced by
uremia and hemodialysis. Semin Dial. 22, 442–4 (2009) DOI: 10.1111/j.1525-
139X.2009.00597.x
22. N.D.Vaziri: Causes of dysregulation of lipid metabolism in chronic renal failure. Semin
Dial. 22, 644–51(2009) DOI: 10.1111/j.1525-139X.2009.00661.x
23. Ćwiklińska, A., Cackowska, M., Wieczorek, E., Król, E., Kowalski, R., Kuchta, A., ... &
Dębska-Ślizień, A. (2018). Progression of chronic kidney disease affects HDL impact on
lipoprotein lipase (LPL)-mediated VLDL lipolysis efficiency. Kidney and Blood Pressure
Research, 43(3), 970-978.
24. M. Akmal, S.E. Kasim, A.R. Soliman, and S.G. Massry: Excess parathyroid hormone
adversely affects lipid metabolism in chronic renal failure. Kidney Int. 37, 854–8 (1990)
DOI: 10.1038/ki.1990.58
25. N.D. Vaziri, J. Yuan, Z. Ni, S.B. Nicholas, and K.C. Norris: Lipoprotein lipase deficiency in
chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1
expression. Clin Exp Nephrol. 16, 238–43 (2012) DOI: 10.1007/s10157-011-0549-3
26. B. Nasstrom, G. Olivecrona, T. Olivecrona, and B.G. Stegmayr: Lipoprotein lipase during
heparin infusion: lower activity in hemodialysis patients. Scand J Clin Lab Invest. 63, 45–53
(2003) DOI: 10.1080/00365510310000484
27. Reiss, A. B., Voloshyna, I., De Leon, J., Miyawaki, N., & Mattana, J. (2015). Cholesterol
metabolism in CKD. American Journal of Kidney Diseases, 66(6), 1071-1082.
28. K. Jin, B.S. Park, Y.W. Kim, and N.D. Vaziri: Plasma PCSK9 in nephrotic syndrome and in
peritoneal dialysis: a cross-sectional study. Am J Kidney Dis. 63, 584–9 (2014) DOI:
10.1053/j.ajkd.2013.10.042
29. Vaziri, N. D. (2015). Dyslipidemia in Chronic Kidney Disease and Nephrotic Syndrome. In
Dyslipidemias (pp. 137-154). Humana Press, Totowa, NJ.
30. P. Barter, A.M. Gotto, J.C. LaRosa, J. Maroni, M. Szarek, S.M. Grundy, J.J. Kastelein, V.
Bittner, J.C. Fruchart: HDL cholesterol, very low levels of LDL cholesterol, and
cardiovascular events. N Engl J Med. 357, 1301–10 (2007) DOI: 10.1056/NEJMoa064278
31. T.I. Chang, E. Streja, and H. Moradi: Could high-density lipoprotein cholesterol predict
increased cardiovascular risk? Curr Opin Endocrinol Diabetes Obes. 24, 140–7 (2017) DOI:
10.1097/MED.0000000000000318
32. K. Kalantar-Zadeh, J.D. Kopple, N. Kamranpour, A.M. Fogelman, and M. Navab: HDL-
inflammatory index correlates with poor outcome in hemodialysis patients. Kidney Int. 72,
1149–56 (2007) DOI: 10.1038/sj.ki.500249
33. Vaziri, N. D. (2016). HDL abnormalities in nephrotic syndrome and chronic kidney disease.
Nature Reviews Nephrology, 12(1), 37.
34. C. Kopecky, M. Haidinger, R. BirnerGrunberger, B. Darnhofer, C.C. Kaltenecker, G.
Marsche, M. Holzer, T. Weichhart, M. Antlanger, J.J. Kovarik, J. Werzowa, M. Hecking,
 and M.D. Saemann: Restoration of renal function does not correct impairment of uremic
HDL properties. J Am Soc Nephrol. 26, 565–75 (2015) DOI: 10.1681/ASN.2013111219
35. R. Kaseda, K. Jabs, T.E. Hunley, D. Jones, A. Bian, R.M. Allen, K.C. Vickers, P.G. Yancey,
M.F. Linton, S. Fazio, and V. Kon: Dysfunctional high-density lipoproteins in children with
chronic kidney disease. Metabolism. 64, 263–73 (2015) DOI:
10.1016/j.metabol.2014.10.020
36. R. Shroff, T. Speer, S. Colin, M. Charakida, S. Zewinger, B. Staels, G. ChinettiGbaguidi, I.
Hettrich, L. Rohrer, F. O’Neill, E. McLoughlin, D. Long, C.M. Shanahan, U. Landmesser,
D. Fliser, and J.E. Deanfield: HDL in children with CKD promotes endothelial dysfunction
and an abnormal vascular phenotype. J Am Soc Nephrol. 25, 2658–68 (2014) DOI:
10.1681/ASN.2013111212
37. M. Holzer, G. Schilcher, S. Curcic, M. Trieb, S. Ljubojevic, T. Stojakovic, H. Scharnagl,
C.M. Kopecky, A.R. Rosenkranz, A. Heinemann, and G. Marsche: Dialysis Modalities and
HDL Composition and Function. J Am Soc Nephrol. 26, 2267–76 (2015) DOI:
10.1681/ASN.2014030309
38. H. Moradi, N.D. Vaziri, M.L. Kashyap, H.M. Said, and K. Kalantar-Zadeh: Role of HDL
dysfunction in end-stage renal disease: a double-edged sword. J Ren Nutr. 23, 203–6 (2013)
DOI: 10.1053/j.jrn.2013.01.022
39. S. Yamamoto, and V. Kon: Chronic kidney disease induced dysfunction of high density
lipoprotein. Clin Exp Nephrol. 18, 251–4 (2014) DOI: 10.1007/s10157-013-0857-x
40. Maurya, N. K., Sengar, N. S., & Arya, P. (2018). Impact of hemodialysis on lipid profile
among chronic renal failure patients (Regular and Non Regular Haemodialysis). Int J, 7,
363-5.
41. PERKENI (2015). Konsensus Pengelolaan dan Pencegahan Diabetes Mellitus tipe 2 di
Indonesia. Jakarta. PB PERKENI.
42. Kim EB, Susan MB, Scott B, Heddwen L. Ganong’s Review of Medical Physiology 25th
edition. Brooks. McGrraw Hill Company; 2016. Fat Metabolism In Diabetes; pp. 437.
43. Sone H, Tanaka S, Tanaka S, Iimuro S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S,
Katayama S, Ohashi Y, Akanuma Y, Yamada N; Japan Diabetes Complications Study
Group. Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for
coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan
Diabetes Complications Study (JDCS). J Clin Endocrinol Metab. 2011, 96: 3448-3456
44. Vergès B: Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia. 2015;
58: 886-899
45. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung
T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J: Effects of extended-
release niacin with laropiprant in high-risk patients N. Engl. J. Med. 2014; 371, 203-212
46. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon
J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR,
Brewer B; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for
coronary events N. Engl. J. Med., 2007; 357: 2109-2122
47. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK,
Hindy G, dkk. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian
randomisation study. Lancet. 2012; 380: 572-580
48. Srivastava RAK: Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of
cardiovascular disease. Mol Cell Biochem. 2018; 440: 167-187
49. Dobiasova M. AIP--atherogenic index of plasma as a significant predictor of cardiovascular
risk: from research to practice. Vnitr Lek. 2006;52:64-71.